A complete Series A financial model for Biotech startups. Revenue model, unit economics, hiring plan, cash flow projections, and funding scenarios — structured for investor review.
Projection Horizon
5 years (monthly for Years 1-2, annual for Years 3-5)
Model Tabs
8 core tabs
Format
Excel + Google Sheets
Scalability of the revenue model and efficiency of the go-to-market. Series A investors validate that the growth engine is repeatable and unit economics improve with scale.
Biotech financial models must include a probability-weighted NPV analysis. Investors value companies on risk-adjusted NPV of the program, not DCF of current revenue. Include a sensitivity table showing NPV at different PoS assumptions.
Milestone-based funding model with pre-commercial phase tracking. Map funding events (SBIR awards, partnerships, equity rounds) to clinical trial stages and regulatory milestones.
Series A models are reviewed by investment committee analysts. Include a data room version with formula audit trail turned on. Avoid hardcoded numbers in cells — every input should flow from the assumption dashboard.
Three scenarios: upside (125% of plan), base (100%), and downside (70%). Include key assumption levers for each scenario and the capital required in each path.
A Series A Biotech financial model should cover 5 years (monthly for Years 1-2, annual for Years 3-5) of projections with these tabs: Executive Summary Model, Revenue Model with Cohorts, Unit Economics Dashboard, Headcount Plan by Department, Departmental P&L, Cash Flow Forecast, Funding Scenarios, Sensitivity Analysis. Scalability of the revenue model and efficiency of the go-to-market. Series A investors validate that the growth engine is repeatable and unit economics improve with scale.
Milestone-based funding model with pre-commercial phase tracking. Map funding events (SBIR awards, partnerships, equity rounds) to clinical trial stages and regulatory milestones. The key revenue drivers are: Collaboration and partnership revenue by agreement; Government grant and SBIR/STTR funding; Licensing milestone payments; Future royalty revenue (post-approval, risk-adjusted).
Biotech unit economics at the Series A stage should include: Cost per patient enrolled in clinical trials; Cost per milestone achieved; NPV of risk-adjusted royalty stream; Cost of goods manufactured (COGS) at commercial scale. Biotech financial models must include a probability-weighted NPV analysis. Investors value companies on risk-adjusted NPV of the program, not DCF of current revenue. Include a sensitivity table showing NPV at different PoS assumptions.
Series A models are reviewed by investment committee analysts. Include a data room version with formula audit trail turned on. Avoid hardcoded numbers in cells — every input should flow from the assumption dashboard. Start with the smallest unit of your business (one customer, one transaction, one seat) and build up from there. Every assumption should have a source or benchmark you can defend in an investor meeting.
Three scenarios: upside (125% of plan), base (100%), and downside (70%). Include key assumption levers for each scenario and the capital required in each path.
Get the Biotech Series A financial model as a pre-built Excel and Google Sheets template. Assumptions dashboard, revenue model, unit economics, and cash flow — ready to customize.
Includes Excel file, Google Sheets version, and model documentation guide